12,783 Shares in Revolution Medicines, Inc. $RVMD Acquired by WINTON GROUP Ltd

Posted by Stanley Muller on Jun 10th, 2026

WINTON GROUP Ltd bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 12,783 shares of the company’s stock, valued at approximately $1,018,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of RVMD. Indiana Trust & Investment Management Co bought a new stake in Revolution Medicines during the 4th quarter worth approximately $32,000. Global Retirement Partners LLC increased its holdings in Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after acquiring an additional 361 shares during the period. Torren Management LLC bought a new stake in Revolution Medicines during the 4th quarter worth approximately $33,000. Darwin Wealth Management LLC bought a new stake in Revolution Medicines during the 4th quarter worth approximately $40,000. Finally, Allworth Financial LP increased its holdings in Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company’s stock worth $46,000 after acquiring an additional 210 shares during the period. Institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the sale, the chief operating officer owned 157,570 shares of the company’s stock, valued at $15,675,063.60. This represents a 2.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Xiaolin Wang sold 2,010 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider directly owned 116,063 shares of the company’s stock, valued at $11,545,947.24. The trade was a 1.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 148,592 shares of company stock worth $20,855,132 over the last ninety days. 7.60% of the stock is owned by company insiders.

Revolution Medicines Trading Up 0.7%

Shares of RVMD opened at $149.55 on Wednesday. The stock has a market capitalization of $31.79 billion, a P/E ratio of -21.15 and a beta of 1.40. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. The firm has a fifty day simple moving average of $137.59 and a two-hundred day simple moving average of $109.04. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $166.50.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same quarter last year, the firm earned ($1.13) EPS. On average, research analysts anticipate that Revolution Medicines, Inc. will post -7.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Truist Financial assumed coverage on shares of Revolution Medicines in a report on Monday, May 18th. They set a “buy” rating and a $179.00 target price on the stock. Oppenheimer upped their target price on shares of Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a report on Monday, June 1st. Stifel Nicolaus reaffirmed a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Royal Bank Of Canada increased their price target on shares of Revolution Medicines from $165.00 to $182.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Finally, Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a report on Monday, June 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $123.72.

View Our Latest Stock Report on Revolution Medicines

Revolution Medicines Profile

(Free Report)

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.